Articles
Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial
Tuan Vu, Ali A Habib, Saiju Jacob, et al
Lancet 2026; 407: 1712-1725
https://doi.org/10.1016/S0140-6736(26)00690-2
Summary
Background
Autoantibody-mediated complement activation drives pathology in acetylcholine receptor (AChR) antibody-positive generalised myasthenia gravis. Newer targeted t...
阅读全文